A
629.47
-8.86 (-1.39%)
| Previous Close | 638.33 |
| Open | 630.20 |
| Volume | 142,479 |
| Avg. Volume (3M) | 266,523 |
| Market Cap | 37,639,974,912 |
| Price / Earnings (Forward) | 101.01 |
| Price / Sales | 20.68 |
| Price / Book | 8.52 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Profit Margin | -2.11% |
| Operating Margin (TTM) | 2.75% |
| Diluted EPS (TTM) | -0.790 |
| Quarterly Revenue Growth (YOY) | 73.30% |
| Total Debt/Equity (MRQ) | 0.80% |
| Current Ratio (MRQ) | 8.53 |
| Operating Cash Flow (TTM) | -259.55 M |
| Levered Free Cash Flow (TTM) | -223.88 M |
| Return on Assets (TTM) | -5.51% |
| Return on Equity (TTM) | -5.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | argenx SE | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 59.76% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 723.00 (Wells Fargo, 14.86%) | Buy |
| Median | 662.50 (5.25%) | |
| Low | 605.00 (Raymond James, -3.89%) | Buy |
| Average | 660.29 (4.90%) | |
| Total | 13 Buy, 1 Hold | |
| Avg. Price @ Call | 588.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 19 Dec 2024 | 723.00 (14.86%) | Buy | 629.47 |
| 01 Nov 2024 | 639.00 (1.51%) | Buy | 595.58 | |
| Evercore ISI Group | 21 Nov 2024 | 706.00 (12.16%) | Buy | 596.74 |
| Oppenheimer | 21 Nov 2024 | 675.00 (7.23%) | Buy | 596.74 |
| 01 Nov 2024 | 646.00 (2.63%) | Buy | 595.58 | |
| HC Wainwright & Co. | 20 Nov 2024 | 617.00 (-1.98%) | Buy | 591.82 |
| 01 Nov 2024 | 617.00 (-1.98%) | Buy | 595.58 | |
| Wolfe Research | 12 Nov 2024 | 697.00 (10.73%) | Buy | 593.95 |
| Scotiabank | 05 Nov 2024 | 715.00 (13.59%) | Buy | 602.47 |
| JP Morgan | 04 Nov 2024 | 670.00 (6.44%) | Buy | 588.67 |
| Baird | 01 Nov 2024 | 650.00 (3.26%) | Hold | 595.58 |
| Guggenheim | 01 Nov 2024 | 665.00 (5.64%) | Buy | 595.58 |
| 26 Sep 2024 | 585.00 (-7.06%) | Buy | 524.58 | |
| JMP Securities | 01 Nov 2024 | 606.00 (-3.73%) | Buy | 595.58 |
| Piper Sandler | 01 Nov 2024 | 620.00 (-1.50%) | Buy | 595.58 |
| Truist Securities | 31 Oct 2024 | 660.00 (4.85%) | Buy | 586.30 |
| Citigroup | 17 Oct 2024 | 635.00 (0.88%) | Buy | 543.84 |
| Raymond James | 10 Oct 2024 | 605.00 (-3.89%) | Buy | 527.25 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |